COVID-19 vaccinesSEROCONVERSIONSOCIOECONOMIC factorsCOMORBIDITYThe article reviews on the immune response to COVID-19 vaccinations in patients with plasma cell dyscrasia, highlighting lower seroconversion rates in these patients, especially those on active anti-CD38 therapy. The stud...
3 months ago Trump bars federal funding to schools with COVID vaccine mandates President Trump on Friday signed an executive order that would strip schools of federal aid if they mandate COVID vaccines, a pool report said. 4 months ago
Scientists are using powerful genomics technologies to explore this and other major questions around the host immune response. Their discoveries will help inform the selection of therapies for clinical trials, vaccine development, and defining high-risk groups. Huge variation in the host response Most ...
Moderna is developing the vaccine in conjunction with the NIAID’s Vaccine Research Center. “These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 μg,” sa...
immune cells called memory B cells and memory T cells. When the body encounters the SARS-CoV-2 virus, it will remember to generate new antibodies and mount a T cell response to counterattack the virus. This type of memory allows for a vaccine to generate longer-lasting protection from ...
SARS-CoV-2 infection and vaccination elicit potent immune responses. Our study presents a comprehensive multimodal single-cell analysis of blood from COVID-19 patients and healthy volunteers receiving the SARS-CoV-2 vaccine and booster. We profiled immune responses via transcriptional analysis and lymp...
Apotential Covid-19 vaccine from the biotech company Novavax showed a promising immune response in a small, early trial, but not without a high rate of mostly mild side effects. The results, published Tuesday, are the latest encouraging sign in the global effort to develop a vaccine for...
While the AdV vaccine platform has been licensed for Ebola, the mRNA vaccine platform represents a newly licensed formulation. Thus, we still have much to learn about how these vaccines mobilize the immune response, the durability of protection and how to further optimize them to protect against ...
“Since elderly individuals face a high risk of serious illness and even death associated with COVID-19 infection, they are an important target population for a COVID-19 vaccine. It is possible that an additional dose may be needed in order to induce a stronger immune response in the ...
Our commitment to combatting coronavirus (COVID-19) disease Since the beginning of the pandemic, we have played a significant role in addressing the devastating impact of COVID-19. The development, manufacture and supply of our COVID-19 vaccine was a principal achievement within our response ...